230 related articles for article (PubMed ID: 30714698)
1. [Our experience with sirolimus for the treatment of complicated vascular anomalies].
Giménez-Aleixandre C; Méndez-Aguirre NA; Martínez-Menchón T; Girón Vallejo Ó; Fernández-Ibieta M; Ferri-Ñíguez B; Villamil V; Sánchez-Sánchez Á; Montoya-Rangel CA; Hernández-Bermejo JP
Cir Pediatr; 2019 Jan; 32(1):28-33. PubMed ID: 30714698
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
3. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for the treatment of children with various complicated vascular anomalies.
Lackner H; Karastaneva A; Schwinger W; Benesch M; Sovinz P; Seidel M; Sperl D; Lanz S; Haxhija E; Reiterer F; Sorantin E; Urban CE
Eur J Pediatr; 2015 Dec; 174(12):1579-84. PubMed ID: 26040705
[TBL] [Abstract][Full Text] [Related]
5. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.
Adams DM; Ricci KW
Hematol Oncol Clin North Am; 2019 Jun; 33(3):455-470. PubMed ID: 31030813
[TBL] [Abstract][Full Text] [Related]
6. A prospective multicenter study of sirolimus for complicated vascular anomalies.
Ji Y; Chen S; Yang K; Zhou J; Zhang X; Jiang X; Xu X; Lu G; Qiu L; Kong F; Zhang Y
J Vasc Surg; 2021 Nov; 74(5):1673-1681.e3. PubMed ID: 34082006
[TBL] [Abstract][Full Text] [Related]
7. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus for the treatment of complicated vascular anomalies in children.
Hammill AM; Wentzel M; Gupta A; Nelson S; Lucky A; Elluru R; Dasgupta R; Azizkhan RG; Adams DM
Pediatr Blood Cancer; 2011 Dec; 57(6):1018-24. PubMed ID: 21445948
[TBL] [Abstract][Full Text] [Related]
9. Angiopoietins as serum biomarkers for lymphatic anomalies.
Le Cras TD; Mobberley-Schuman PS; Broering M; Fei L; Trenor CC; Adams DM
Angiogenesis; 2017 Feb; 20(1):163-173. PubMed ID: 27990590
[TBL] [Abstract][Full Text] [Related]
10. Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review.
Sandbank S; Molho-Pessach V; Farkas A; Barzilai A; Greenberger S
Acta Derm Venereol; 2019 Oct; 99(11):990-996. PubMed ID: 31304557
[TBL] [Abstract][Full Text] [Related]
11. Oral rapamycin: an alternative in children with complicated vascular abnormalities.
Gómez Sánchez A; Redondo Sedano JV; Pérez Alonso V; Martí Carrera ME; Baro Fernández M; Palencia Pérez SI; Gallego Herrero MC; Gómez Fraile A; Delgado Muñoz MD
Cir Pediatr; 2020 Oct; 33(4):183-187. PubMed ID: 33016658
[TBL] [Abstract][Full Text] [Related]
12. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.
Wang Z; Zheng C; Sun H; Yao W; Li K; Ma Y; Zheng S
Dermatology; 2020; 236(3):262-270. PubMed ID: 31896113
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
[TBL] [Abstract][Full Text] [Related]
16. Analysis of mTOR pathway expression in lymphatic malformation and related diseases.
Hori Y; Ozeki M; Hirose K; Matsuoka K; Matsui T; Kohara M; Tahara S; Toyosawa S; Fukao T; Morii E
Pathol Int; 2020 Jun; 70(6):323-329. PubMed ID: 32067331
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
18. Infectious complications of vascular anomalies treated with sirolimus: A systematic review.
Kalbfell R; Cohen-Cutler S; Grisham E; Bereitschaft C; Borst AJ; Green AM; Willis DN; Yaeger L; Blatt J; Sisk BA
Pediatr Blood Cancer; 2024 Jan; 71(1):e30758. PubMed ID: 37933207
[TBL] [Abstract][Full Text] [Related]
19. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series.
Badia P; Ricci K; Gurria JP; Dasgupta R; Patel M; Hammill A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28088. PubMed ID: 31930696
[TBL] [Abstract][Full Text] [Related]
20. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
